These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23441215)

  • 1. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.
    Triulzi T; Casalini P; Sandri M; Ratti M; Carcangiu ML; Colombo MP; Balsari A; Ménard S; Orlandi R; Tagliabue E
    PLoS One; 2013; 8(2):e56761. PubMed ID: 23441215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
    Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
    Lecchi M; Verderio P; Cappelletti V; De Santis F; Paolini B; Monica M; Sangaletti S; Pupa SM; Iorio MV; Bianchi G; Gennaro M; Fucà G; De Braud F; Tagliabue E; Di Nicola M
    Mol Oncol; 2021 May; 15(5):1345-1357. PubMed ID: 33523584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.
    Rybinska I; Sandri M; Bianchi F; Orlandi R; De Cecco L; Gasparini P; Campiglio M; Paolini B; Sfondrini L; Tagliabue E; Triulzi T
    Cells; 2020 Feb; 9(2):. PubMed ID: 32069815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
    Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
    Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic stromal gene signatures in breast cancer.
    Winslow S; Leandersson K; Edsjö A; Larsson C
    Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
    Sangaletti S; Tripodo C; Santangelo A; Castioni N; Portararo P; Gulino A; Botti L; Parenza M; Cappetti B; Orlandi R; Tagliabue E; Chiodoni C; Colombo MP
    Cell Rep; 2016 Sep; 17(1):233-248. PubMed ID: 27681434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
    Winslow S; Lindquist KE; Edsjö A; Larsson C
    BMC Cancer; 2016 Nov; 16(1):841. PubMed ID: 27809802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
    Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
    BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
    Bergamaschi A; Tagliabue E; Sørlie T; Naume B; Triulzi T; Orlandi R; Russnes HG; Nesland JM; Tammi R; Auvinen P; Kosma VM; Ménard S; Børresen-Dale AL
    J Pathol; 2008 Feb; 214(3):357-67. PubMed ID: 18044827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer.
    Tiwari S; Triulzi T; Holton S; Regondi V; Paolini B; Tagliabue E; Bhargava R
    Sci Rep; 2020 Mar; 10(1):5442. PubMed ID: 32214177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of the tumor microenvironment during breast cancer progression.
    Ma XJ; Dahiya S; Richardson E; Erlander M; Sgroi DC
    Breast Cancer Res; 2009; 11(1):R7. PubMed ID: 19187537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome.
    Myhre S; Mohammed H; Tramm T; Alsner J; Finak G; Park M; Overgaard J; Børresen-Dale AL; Frigessi A; Sørlie T
    PLoS One; 2010 Nov; 5(11):e14002. PubMed ID: 21124964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
    Sakurai M; Miki Y; Takagi K; Suzuki T; Ishida T; Ohuchi N; Sasano H
    Breast Cancer Res; 2017 Jun; 19(1):70. PubMed ID: 28629450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations.
    Niemiec J; Adamczyk A; Małecki K; Ambicka A; Ryś J
    Clin Breast Cancer; 2013 Apr; 13(2):119-28. PubMed ID: 23375518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal responses among common carcinomas correlated with clinicopathologic features.
    Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
    Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
    Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
    Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
    Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
    Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.